P I Industries Ltd Q4 FY2023 Concall Summary

Key Takeaways

• FY23 delivered 23% revenue growth with margin expansion: EBITDA margin improved 223 bps to 24%, PAT rose 46%, and operating cash flow more than doubled as working capital days fell sharply.
• FY24 guided at 18-20% growth, volume-led: Management expects no significant price or currency tailwinds; the growth is to be driven entirely by volume scale-up of existing molecules and 4-5 new commercializations.
• Pharma entry is now concrete, with twin CDMO/CRO acquisitions: The acquired entities are projected to add Rs. 550-600 crore revenue at 15-18% EBITDA margin, but management expects a 2.5-3 year journey to match PI's current return profile.
• Cash deployment is a multi-year strategic story: With the ECB fully repaid and strong operating cash flow, PI is evaluating pharma bolt-ons, domestic portfolio strengthening, near-shoring, and global manufacturing expansion, but no timeline is committed.
• What to watch next quarter: The pace of pharma integration planning and any incremental inorganic moves, the trajectory of gross margins after Q4's mix-driven sequential dip, and whether volume growth tracks to the 18-20% guided range in H1.

FY23 Performance & Q4 Drivers

• Export engine drove the year: 26% export growth came from an 11% volume increase and 15% from product mix, price pass-through, and currency, with four new products commercialized during the year.
• Q4 revenue growth moderated to 12%: Export volumes declined 2% in the quarter, which management described as in line with the annual supply plan rather than a demand signal, while price/mix contributed 17%.
• Gross margin improved 74 bps YoY to 45% in Q4: The sequential dip of ~2.5% was directly linked to product mix change, plus ~1% from annual provisions and one-time strategic initiative costs that will not recur.
• Operating leverage and mix drove EBITDA margin to 24% for FY23: A 223 bps improvement, with Q4 EBITDA up 13% on tight fixed overhead control despite the softer topline quarter.
• PAT jumped 46% for the full year: The effective tax rate improved by 14.9 percentage points due to the growing share of export revenue in the mix.
• Working capital transformation: Trade working capital days reduced to 79 from 103, and operating cash flow before tax rose to Rs. 1,757 crore from Rs. 704 crore, driven by inventory normalization after COVID-era buffer stock unwound.
• New product contribution held steady: Revenue from products commercialized in the last 4-5 years contributed 17-18% of revenue, up from 16-17% last year, a range management considers normal given 15-20 year product lifecycles and multi-year scale-up timelines.

Rajnish Sarna: "If you look at the cycle of 15-20 years because that is the lifecycle of a product; if you look at the history of the last 4-5 years, it is between that range of 16% to 18% because that is the typical scale-up time lifecycle for a new product."

FY24 Guidance: Volume-Led Growth with Margin Expansion

• 18-20% revenue growth guided for FY24: The growth is expected to be entirely volume-driven, with no significant price increases or currency movement factored in, and it excludes any contribution from the pharma acquisitions.
• Volume growth to be broad-based: Management emphasized that growth will be widespread across existing products scaling up and 4-5 new molecules commercialized, not concentrated in any single product.
• Margin improvement expected over FY23 levels: Operating leverage from 18-20% volume growth, plus efficiency initiatives in manufacturing and marketing, are expected to lift EBITDA margins further, though management declined to quantify the target.
• Tax rate guided at 15-16% for FY24: The lower rate reflects the continued benefit of a rising export revenue share.
• Revenue skewness is limited: Domestic business is weighted ~60% to H1, while exports are evenly distributed across halves, so no major half-yearly skew is expected.
• CAPEX in ag-chem set at Rs. 850-900 crore: This includes Rs. 300 crore carried over from FY23 and Rs. 600 crore for core business areas, with benefits to be realized from FY25 onwards. Two new multi-product plants are part of this plan.

Pharma Foray: Acquisitions, Integration & Return Timeline

• Twin acquisitions mark the pharma entry: PI announced the acquisition of pharma CDMO and CRO entities on 27 April 2023, describing it as an accelerated beginning to its pharma journey.
• Acquired entities projected at Rs. 550-600 crore revenue: The consolidation timing will determine the exact FY24 contribution, and the revenue is excluded from the 18-20% organic growth guidance.
• Pharma EBITDA margin expected at 15-18% initially: Development spend in the initial years will keep margins below PI's consolidated level, with a 2.5-3 year timeline to match PI's current margin and return profile.
• Integration work is underway with global advisors: Management is working with advisors on integration and transformation value creation initiatives but declined to share details on asset turns or incremental projects, saying assessment is still in progress.
• Pharma CAPEX is tentative at ~USD 10-12 million for FY24: Numbers will be firmed up once full control of the acquired entities is taken.

Rajnish Sarna: "The kind of acquisitions and the differentiated model that we are planning to build, it will take anywhere between 2.5 to 3 years for us to get to the level where it will start matching margin and return profile that we have in PI today."

Balance Sheet & Capital Allocation

• ECB loan fully repaid during FY23: The repayment included a one-time forex impact recorded in other expenses, contributing to the Q4 cost base.
• Cash deployment is a multi-year strategic agenda: Management identified pharma bolt-ons, strengthening the domestic product portfolio, near-shoring, and expanding the global manufacturing footprint beyond India as priorities, and is actively evaluating inorganic opportunities.
• No timeline commitment on deployment: Management emphasized that opportunities must be the right strategic fit on technology and scalability, and declined to answer how soon any deal might materialize.
• Asset return improvement is an objective post-integration: PI aims to improve asset turns, margins, and asset returns after the initial integration period of new businesses, though no quantified targets were given.
• Working capital has further improvement scope: Both domestic and export sides have room for incremental reduction, but management cautioned against extrapolating the current pace of improvement.

Mayank Singhal: "How soon is not a question that we can answer at the moment because it's got to be right opportunity which fits in and is in the strategic right path of PI's intent which is technology and scalability in the areas which we want to operate in and the right strategic fit."

Business Model & Competitive Position

• Early-stage molecule focus insulated PI from generic headwinds: Management attributed resilient demand to PI's position in early-stage molecules, where demand is largely unaffected by the pricing pressure seen in matured generics.
• China+1 and EU chemical industry decline are structural tailwinds: Management cited India's specialty chemical export potential to scale 10x between 2023 and 2030, with the domestic chemicals market projected at \$850 billion to \$1 trillion in ~15 years.
• Domestic business delivered 12% growth with 8% volume: New brand launches saw good acceptance, and PI delivered one of the highest numbers of new launches in the industry during the year.
• New product pipeline breadth supports growth visibility: The four products commercialized in FY23 plus existing molecules scaling up provide a widespread base, and management expects to sustain a pace of 4-5 commercializations annually.
• Domestic new products have larger market potential: These are multicrop-by-segment products, while export new products are active ingredients or intermediates of large global molecules with strong growth potential.

Mayank Singhal: "PI, which is mainly engaged in the early-stage molecules, the demand scenario for such products largely remained unaffected given the inherent nature of its model."

Guidance & Commitments

Key Metrics